Allen v. Takeda Pharms. N. Am., Inc. (In re Actos®), Case No. 6:12-cv-00064-RFD-PJH
Decision Date | 27 October 2014 |
Docket Number | MDL No. 6:11-md-2299,Case No. 6:12-cv-00064-RFD-PJH |
Parties | IN RE: ACTOS® (PIOGLITAZONE) PRODUCTS LIABILITY LITIGATION This Document Applies To: Allen et al. v. Takeda Pharmaceuticals North America, Inc. et al. |
Court | U.S. District Court — Western District of Louisiana |
Pending before this Court is the Defendants' Rule 59 Motion for a New Trial,1 filed on behalf of all Defendants.2 The Defendants have moved, pursuant to Rule 59 of the Federal Rules of Civil Procedure, for a new trial on all of the Plaintiffs' claims and/or argue for reduction of the punitive damages award.3 Briefing in this matter now being complete, the matter is ripe for ruling.4 For the following reasons, the motion will be GRANTED IN PART and DENIED IN PART.
These proceedings were instituted by the Judicial Panel on Multidistrict Litigation by order dated December 29, 2011.5 After little more than a year of litigation, upon request and agreement of the parties, this Court scheduled the trial in "Allen v. Takeda Pharmaceuticals North America, Inc.," Civil Action No. 12-0064, as an early trial or bellwether trial. The trial began on January 27, 2014; eleven weeks later, on the last day of trial, this Court gave the following instruction to the jury to guide its determination of whether the factual predicate for punitive damages existed in this case, i.e., whether the jury found that Defendants had engaged in wanton and reckless disregard of the effects of their actions.6
Now, who is a relevant "superior officer" under the law? Under applicable law, a "superior officer" relevant to this inquiry is someone in management who has authorized, participated in, consented to, or ratified the conduct that led to the liability, or who was pursuing a recognized business system of Takeda, as to Takeda, or Eli Lilly, as to Eli Lilly.
Now, the term "superior officer" is more than an agent or "ordinary" officer or employee vested with just some supervisory or decision-making responsibility, but must be someone whose actions can be equated with participation by the company. However, a "superior officer" need not be someone located in the executive suite or the topmost reaches of the company, but he or she must have a high enough level of responsibility within the company that his or her participation in the wrongdoing renders the company blameworthy and arouses the "institutional conscience" for corrective action.
So, if you find that either the conduct of a "superior officer" of Takeda or the conduct of a "superior officer" of Eli Lilly does not meet the standard I have just explained, you will answer "no" on the Jury Verdict Form as to that company. On the other hand, if you find the Plaintiffs have proven, by a preponderance of the evidence, that the conduct of a "superior officer" of Takeda or the conduct of a "superior officer" of Lilly does meet the standard I have just explained, you should answer "yes" on the Jury Verdict Form.7
After due deliberation, the jury found that both Takeda and Lilly had engaged in wanton and reckless disregard of the effects of their actions.8 Once this factual predicate for the award of punitive damages had been found, this Court asked the jury to return to open court and only then provided the jury with the following additional instruction to guide its determination of the amount of the punitive damage awards:
Now you may also consider Takeda's and Lilly's financial condition and the impact your punitive damages award will have on Takeda and Lilly.9
This Court, also, instructed the jury that the parties had reached certain stipulations of fact, that those stipulations had been accepted by the Court, and, therefore, that the jury was required to accept these facts as proven. The stipulations of fact agreed to by the parties are as follows:
The net sales of Actos® in the United States - Your Honor, we've stipulated to individual amounts that we can put into the record that the jury can see, but in the interest of time, they range from [$]582 million in the early going, to by the year 2002, [$]1.1 billion; by the year 2006, [$]2.1 billion; by the year 2009, [$]2.7 billion; 2010, [$]3 billion; 2011, [$]2.6 billion; and then it tales [sic] back to [$]815,000 for 2012, for a total Actos® net sales between 1999 and 2012 of $24 billion dollar.
The total Actos® prescriptions written as of June 15, 2011, is more than 100 million. The total number of patients that were prescribed Actos® as of June 15, 2011, is more than 10 million.
And that concludes the stipulated tender.10
The trial ended on April 7, 2014 when the jury issued its complete verdict.11 After finding in favor of the Plaintiffs on all factual and causation questions, the jury made the following compensatory damage awards:
To continue reading
Request your trial